Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Amy Werremeyer, Sydney Mosher, Heidi Eukel, Elizabeth Skoy, Jayme Steig, Oliver Frenzel & Mark A. Strand. (2021) Pharmacists’ stigma toward patients engaged in opioid misuse: When “social distance” does not mean disease prevention. Substance Abuse 42:4, pages 919-926.
Read now
Read now
Articles from other publishers (17)
David Chavanne, Jasjit S. Ahluwalia & Kimberly Goodyear. (2023) The effects of race and class on community-level stigmatization of opioid use and policy preferences. International Journal of Drug Policy 120, pages 104147.
Crossref
Crossref
Simon Clay, Carla Treloar, Louisa Degenhardt, Jason Grebely, Michael Christmass, Chris Gough, Jeremy Hayllar, Mike McDonough, Charles Henderson, Sione Crawford, Michael Farrell & Alison Marshall. (2023) ‘I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue. International Journal of Drug Policy 115, pages 104002.
Crossref
Crossref
Minji Sohn, Chris Delcher, Jeffery C. Talbert, Yue Cheng, Yong Xu, Emmanuel D. Jadhav & Patricia R. Freeman. (2023) The Impact of Naloxone Coprescribing Mandates on Opioid-Involved Overdose Deaths. American Journal of Preventive Medicine 64:4, pages 483-491.
Crossref
Crossref
Stephanie A. Hooker, A. Lauren Crain, Amy B. LaFrance, Sheryl Kane, J. Konadu Fokuo, Gavin Bart & Rebecca C. Rossom. (2023) A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians. Addiction Science & Clinical Practice 18:1.
Crossref
Crossref
Bennett Allen, Victoria A. Jent & Magdalena Cerdá. (2022) Cycles of Chronic Opioid Therapy Following Mandatory Prescription Drug Monitoring Program Legislation: A Retrospective Cohort Study. Journal of General Internal Medicine 37:16, pages 4088-4094.
Crossref
Crossref
Samantha Davis, Bruce Wallace, Thea Van Roode & Dennis Hore. (2022) Substance Use Stigma and Community Drug Checking: A Qualitative Study Examining Barriers and Possible Responses. International Journal of Environmental Research and Public Health 19:23, pages 15978.
Crossref
Crossref
Louisa Picco, Paul Sanfilippo, Ting Xia, Tina Lam & Suzanne Nielsen. (2022) How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A randomised controlled factorial experiment. International Journal of Drug Policy 109, pages 103856.
Crossref
Crossref
Sarah Haines, Ashley Lam, Michael Savic & Adrian Carter. (2022) Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline. International Journal of Drug Policy 109, pages 103847.
Crossref
Crossref
Shari S. Rogal, Matthew J. Chinman, William DeMonte, Sandra Gibson, Stephanie Hoyt-Trapp, Gloria J. Klima, Naudia L. Jonassaint, Jane M. Liebschutz, Kevin L. Kraemer & Jessica Merlin. (2022) Using Intervention Mapping to Develop a Novel Pain Self-Management Intervention for People with Cirrhosis. Digestive Diseases and Sciences 67:11, pages 5063-5078.
Crossref
Crossref
Dimi Hoppe, Leila Karimi & Hanan Khalil. (2022) Mapping the research addressing prescription drug monitoring programs: A scoping review. Drug and Alcohol Review 41:4, pages 803-817.
Crossref
Crossref
Rachel Chernick, Bennett Allen & Alex Harocopos. (2021) Primary Care Implementation of a Mandatory Prescription Drug Monitoring Program in New York City. The Journal of Behavioral Health Services & Research 49:2, pages 122-133.
Crossref
Crossref
Alex Harocopos, Bennett Allen & Rachel Chernick. (2022) Primary care provider perspectives on and utilization of a mandatory prescription drug monitoring program in New York City. Family Practice 39:2, pages 264-268.
Crossref
Crossref
Alice M. Ellyson, Jevay Grooms & Alberto Ortega. (2021) Flipping the script: The effects of opioid prescription monitoring on specialty‐specific provider behavior. Health Economics 31:2, pages 297-341.
Crossref
Crossref
Todd Schneberk. (2021) Shifting the Paradigm: Patient-Centered Emergency Department Opioid Use Disorder Treatment. Annals of Emergency Medicine 78:1, pages 80-83.
Crossref
Crossref
Julia E. Szymczak. (2021) Mandates are not magic bullets: Leveraging context, meaning and relationships to increase meaningful use of prescription monitoring programs. Pharmacoepidemiology and Drug Safety 30:7, pages 979-981.
Crossref
Crossref
Cara L. Sedney, Patricia Dekeseredy & Treah Haggerty. (2021) Stigmatizing Diagnoses in Neurosurgery: A Narrative Review. World Neurosurgery 145, pages 25-34.
Crossref
Crossref
Erin Oldenhof, Jane Anderson-Wurf, Kate Hall & Petra K. Staiger. (2019) Beyond Prescriptions Monitoring Programs: The Importance of Having the Conversation about Benzodiazepine Use. Journal of Clinical Medicine 8:12, pages 2143.
Crossref
Crossref